Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

Renner, R; Pfützner, Andreas; Trautmann, Michael E.; Harzer, Oliver; Sauter, Karin; Landgraf, R

doi:10.2337/diacare.22.5.784

Cited by 158 publications

(98 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We ultimately identified 27 randomised controlled trials that compared SAI analogues with regular insulin using either CSII or IIT as injection regimens. Of these, 22 studies were performed with type 1 diabetic patients [5,6,7,10,11,12,14,15,16,38,39,40,41,42,43,44,45,46,47,48,49,50] and five studies had a combined study population of type 1 and type 2 diabetic patients [8,51,52,53,54]. Table 1 summarises the characteristics of the trials included in our analysis.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

Siebenhofer¹,

Plank²,

Berghold

et al. 2004

Diabetologia

View full text Add to dashboard Cite

Aims/hypothesis. This study aimed to compare the effect of treatment with short-acting insulin (SAI) analogues versus structurally unchanged short-acting insulin (regular insulin) on glycaemic control and on the risk of hypoglycaemic episodes in type 1 diabetic patients using different insulin treatment strategies. Methods. We performed a meta-analysis of 27 randomised controlled trials that compared the effect of SAI analogues with regular insulin in patients with type 1 diabetes mellitus. The treatments were administered either via continuous subcutaneous insulin infusion (CSII) or by conventional intensified insulin therapy (IIT) with short-acting insulin injections before meals and basal insulin administered once or twice daily in most cases. Results. HbA 1 c levels were reported for 20 studies. For studies using CSII, the weighted mean difference between values obtained using SAI analogues and regular insulin was −0.19% (95% CI: −0.27 to − 0.12), whereas the corresponding value for injection studies was −0.08% (95% CI: −0.15 to −0.02). For the analysis of overall hypoglycaemia, we used the results from nine studies that reported the mean frequency of hypoglycaemic episodes per patient per month. For studies using CSII, the standardised mean difference between SAI analogues and regular insulin was −0.07 (95% CI: −0.43 to 0.28), whereas for IIT studies the corresponding value was −0.04 (95% CI: −0.24 to 0.16). Conclusions/interpretation. Taking into consideration the low quality of the trials included, we can conclude that use of a short-acting insulin analogue in CSII therapy provides a small, but statistically significant improvement in glycaemic control compared with regular insulin. An even smaller effect was obtained with the use of ITT. The rate of overall hypoglycaemic episodes was not significantly reduced with short-acting insulin analogues in either injection regimen.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Despite the theoretical superiority of SAI analogues over regular insulin, the efficacy of SAI analogues in the treatment of diabetic patients is still unclear. Some studies have reported improved metabolic control and reduced hypoglycaemic episodes [5,6,7,8,9,10,11,12,13], whereas others failed to show a positive effect [14,15,16].…”

Section: Introductionmentioning

confidence: 99%

Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

Siebenhofer¹,

Plank²,

Berghold

et al. 2004

Diabetologia

View full text Add to dashboard Cite

show abstract

“…Bode and colleagues 113 compared two analogue insulins, lispro and aspart, whereas the other studies included insulin lispro. Randomisation and allocation concealment were adequate in the parallel RCT, 113 but the method of randomisation was not reported in the five crossover studies [114][115][116][117][118] ( Table 18). The similarity of the groups at baseline was reported in two studies, 113,117 and all studies reported eligibility criteria.…”

Section: Analogue Versus Soluble Insulin In Csii Quantity and Qualitymentioning

confidence: 99%

“…Six studies (one parallel RCT 113 and five randomised crossover studies [114][115][116][117][118] ) comparing rapid-acting analogues with soluble insulin in CSII were included in the review and are reported in Tables 18-23 and Appendices 9 and 13. Bode and colleagues 113 compared two analogue insulins, lispro and aspart, whereas the other studies included insulin lispro.…”

Section: Analogue Versus Soluble Insulin In Csii Quantity and Qualitymentioning

confidence: 99%

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Colquitt¹,

Green²,

Sidhu³

et al. 2004

Health Technol Assess

106

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents, York Publishing Services by:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to York Publishing Distribution and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.ncchta.org/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public, consumer groups and professional bodies such as Royal Colleges and NHS Trusts.Research suggestions are carefully considered by panels of independent experts (including consumers) whose advice results in a ranked list of recommended research priorities. The HTA Programme then...

show abstract

“…Outro esquema de distribuição da dose basal, menos usado, é o método de Renner (12), no qual as doses são variáveis, nos diversos horários do dia, desde o início do tratamento, segundo um programa que privilegia maiores doses de insulina para os períodos de maiores necessidades (alvorecer, entardecer) e menores doses do final da noite até a madrugada.…”

Section: Ajuste Da Dose Basalunclassified

Uso de bomba de infusão subcutânea de insulina e suas indicações

Minicucci

2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESuMO tanto a bomba de infusão de insulina quanto a terapêutica de múltiplas doses de insulina (Mdi) são meios efetivos de implementar o manejo intensivo do diabetes melito tipo 1 (dM1), com o objetivo de chegar a níveis glicêmicos quase normais e obter-se um estilo de vida mais flexível. A terapia com bomba de infusão de insulina é tão segura quanto a Mdi e tem vantagens sobre ela, sobretudo em pacientes com hipoglicemias freqüentes, com um fenôme-no do alvorecer importante, com gastroparesia, na gravidez, em crianças e em pacientes com dM1 e com um estilo de vida errático. A terapia com bomba de infusão de insulina possibilita maior probabilidade de se alcançar melhor controle glicêmico com menos hipoglicemia, hipoglicemias assintomáticas e melhor qualidade de vida. Além disso, os riscos e os efeitos adversos da terapêutica insulínica em pacientes com dM1 em insulinização intensiva são menores nos pacientes usando esta terapia, quando comparados a pacientes em Mdi. Para tal, o ajuste cuidadoso das doses basais e de bólus e o seguimento adequado do paciente são vitais. Both continuous subcutaneous insulin infusion (csii) and Multiple daily injections (Mdi) are effective ways of implementing intensive management of dM1 to attain near normal glycemic levels and a more flexible lifestyle. csii is as safe as Mdi and has some advantages over it mostly in diabetic patients with frequent hypoglycemias with important dawn phenomenum, gastroparesia, during pregnancy, in children and in patients with an erratic way of living. csii allows a better chance to reach better glycemic control with less hypoglycemia, asymptomatic hypoglycemias and a better quality of life. Besides, risks are lower and adverse events are less frequent in dM1 patients under csii as compared to Mdi. to obtain results like this, a careful adjustment of basal and boluses insulin doses and an adequate patient follow-up are essential. (Arq Bras Endocrinol Metab 2008;52/2:340-348)

show abstract

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

Abstract: Insulin lispro is a suitable and very convenient pump insulin that may result in an improvement of long-term glucose control during CSII treatment. Its safety profile does not differ from that of regular human insulin.

Cited by 158 publications

References 2 publications

Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Uso de bomba de infusão subcutânea de insulina e suas indicações

Contact Info

Product

Resources

About